Chronic treatment of MI-induced rats with the synthetic PPARδ activator GW610742X normalized FAO rates in a dose-dependent manner, and treated mice showed a sharp reduction in cell hypertrophy in the right ventricle and a reduced rate lung congestion, suggesting PPARδ intervention as a plausible therapeutic approach for HF [159]. The gene discussed is PPARD; the disease is hydrops fetalis.